Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)

Inclusion Criteria for study and fellow eye: • Patients with visual impairment secondary to central retinal vein occlusion (CRVO) with a BCVA between 24 and 73 letters in one eye and at least 35 letters in the other eye. Exclusion Criteria: * Pregnant or nursing women or women of child bearing potential unless using an effective contraception \- Stroke or myocard infarction within 3 months prior to study * History of malignancy within the past 5 years * Uncontrolled hypertension * Active infection or inflammation in any eye * use of corticosteroids for at least 30 days in the last 6 months * treatment with anti-angiogenic drugs in any eye within last 3 months * Panretinal or focal/drid laser photocoagulation within the last 3 and 4 months respectively